Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Fiala, Ondřej; Šorejs, Ondřej; Šustr, Jan; Kučera, Radek; Topolčan, Ondřej; Fínek, Jindřich

doi:10.21873/anticanres.14063

Cited by 25 publications

(23 citation statements)

References 45 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the development of irAEs) is present in patients treated with immune checkpoint inhibitors. These irAEs may involve the dermatologic, gastrointestinal and endocrine systems ( 28 , 29 ). In this study, various irAEs were reported in 57 out of 124 patients, with skin disorders the most common ( n = 22), followed by thyroid dysfunction ( n = 21) and vitiligo ( n = 14) ( Supplementary Table S4 ).…”

Section: Discussionmentioning

confidence: 99%

“…The relative risk for developing dermatologic irAEs was 2.3 in patients with various cancers treated with nivolumab, and vitiligo is characteristically reported in trials investigating the use of these inhibitors in malignant melanoma ( 30 ). In addition, dermatologic irAEs are reportedly associated with a higher response rate and improved survival in patients with melanoma treated with PD-1 inhibitors, including nivolumab ( 28 , 29 ). Generally, dermatologic irAEs associated with nivolumab treatment are primarily low grade and manageable with established safety guidelines ( 7 , 8 ); therefore, the development of dermatologic irAEs seems to have a clinical benefit ( 29 , 31 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)

Yamazaki¹,

Takenouchi

Nakamura

et al. 2021

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Background Nivolumab, the anti-programmed cell death protein 1 antibody, has been approved for advanced melanoma, mainly based on evidence from Western countries. The profile of melanoma differs between Caucasian and Asian patients. This study was performed to obtain post-marketing data of nivolumab in Japanese patients with advanced melanoma. Methods This prospective, observational study involved patients with unresectable or metastatic melanoma treated with nivolumab at dosages of 2 mg/kg every 3 weeks or 3 mg/kg every 2 weeks. The primary endpoints were objective response rate and overall survival. The secondary endpoints were progression-free survival and the objective response rate according to immune-related Response Evaluation Criteria in Solid Tumours. Result Among 124 patients analysed, mucosal melanoma was the most common subtype, followed by acral lentiginous, nodular, superficial spreading and lentigo maligna melanoma. Response Evaluation Criteria in Solid Tumours evaluation showed an objective response rate of 17.7%. The median survival time was 15.93 months, and the 1-year overall survival rate was 66%. Outcomes were not significantly different among melanoma subtypes. Better overall survival and/or progression-free survival but not objective response rate were associated with performance status 0, lower levels of lactate dehydrogenase, C-reactive protein and neutrophil-to-lymphocyte ratio. Patients with immune-related adverse events showed a better objective response rate, 3-month landmark overall survival and progression-free survival than patients without immune-related adverse events. Conclusion The objective response rate and median survival time in Japanese patients treated with nivolumab were lower in daily practice than the >30% and >30 months, respectively, seen in global phase III trials. The occurrence of immune-related adverse events may be a predictor for survival and response to treatment with nivolumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)

Yamazaki¹,

Takenouchi

Nakamura

et al. 2021

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…However, immune-checkpoint inhibitors can induce immunerelated adverse events (irAEs) including rash, colitis, hepatitis, endocrinopathies, and pneumonitis (2,3). IrAEs have been associated with patient characteristics, efficacy and total number of doses of PD-1 inhibitors (4)(5)(6). In patients with various malignancies treated with immunecheckpoint inhibitors, irAEs are associated with better survival (7)(8)(9)(10)(11)(12)(13).…”

mentioning

confidence: 99%

Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

Kobayashi

Iikura

Hiraide

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-tolymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma. Patients and Methods Study design. We retrospectively reviewed the medical records of all patients with mRCC who were previously treated with VEGFtargeted therapy and who started treatment with nivolumab at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research between September 2016 and September 2018. This review identified 53 eligible patients who received nivolumab monotherapy. Patients with known active or suspected autoimmune disease and patients requiring immunosuppressive medications were excluded from participation in this study. Treatment regimen and study drugs. Based on the results from a previous clinical trial (1), patients were given nivolumab every 2 weeks until the end of treatment or follow-up. In Japan, the 2647 This article is freely accessible online.

show abstract

“…A 3-year follow-up study of 126 squamous cell carcinoma of the head and neck (SCCHN) patients receiving anti-PD-1/L1 therapy demonstrated that SMARCA4 mutation and/or frameshift were more frequently observed in responders than nonresponders 67 . Consistently, a case report of thoracic sarcoma showed that SMARCA4 deficiency resulted in notable clinical response to Nivolumab (anti-PD-1) treatment 68 . Of note, in a small cohort study, four small-cell carcinomas of the ovary, hypercalcemic type (SCCOHT) patients showed a notable response to anti-PD-1 immunotherapy.…”

Section: Smarca4/brg1mentioning

confidence: 71%

Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers

et al. 2021

View full text Add to dashboard Cite

Mammalian SWI/SNF complex is a key chromatin remodeler that reshapes nucleosomes and regulates DNA accessibility. Mutations in SWI/SNF subunits are found in a broad spectrum of human cancers; however, the mechanisms of how these aberrations of SWI/SNF complex would impact tumorigenesis and cancer therapeutics remain to be elucidated. Studies have demonstrated that immune checkpoint blockade (ICB) therapy is promising in cancer treatment. Nevertheless, suitable biomarkers that reliably predict the clinical response to ICB are still lacking. Emerging evidence has suggested that SWI/SNF components play novel roles in the regulation of anti-tumor immunity, and SWI/SNF deficiency can be therapeutically targeted by ICB. These findings manifest the prominence of the SWI/SNF complex as a stratification biomarker that predicts treatment (therapeutic) response to ICB. In this review, we summarize the recent advances in ICB therapy by harnessing the cancer-specific vulnerability elicited by SWI/SNF deficiency. We provide novel insights into a comprehensive understanding of the underlying mechanisms by which SWI/SNF functions as a modulator of anti-tumor immunity.

show abstract

Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Abstract: Fiala et al: Immune-related Adverse Effects and Outcome of Patients Treated With Immunotherapy (Review)

Cited by 25 publications

References 45 publications

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)

Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers

Contact Info

Product

Resources

About